Skip to contentC
Cryo Cell International Inc
C
CCELCryo Cell International Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$8.02M$8.02Mderived+1.9% vs Q4 2023 Net Income-$1.86M-$1.86MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cryo Cell International Inc · CIK 862692 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$122,347N/M Operating Cash Flowderived$2,156,993−35.5% Free Cash Flowderived$2,148,645+31.9% Margins · derivedOperating margin-1.5%+203.8 pt vs Q4 2023
Net margin-23.2%+118.9 pt vs Q4 2023
ended Nov 30, 2024 · filed Feb 28, 2025 · 90 d after period end